Location of Repository

Rifampicin therapy in Escherichia coli gastroenteritis

By Yehezkel Naveh and Abraham Friedman

Abstract

Eight infants aged 2-4 months suffering from gastroenteritis associated with enteropathic Escherichia coli were treated with rifampicin. Seven of them had serotype 0125: B15 and the eighth had serotype 0126: B16. One of them had septicaemia due to E. coli 0125: B15. Five cases were initially treated with antibiotics and chemotherapeutic agents to which E. coli was shown to be sensitive but without results. Rifampicin was effective in curing gastrointestinal signs and eradicating the bacilli in seven of eight infants. The drug was given in a dose of 15-25 mg/kg/day divided into two equal parts, for 7 days in most of the cases. No untoward side effects were observed clinically in any of the cases. Our experience should encourage the use of this agent in controlling outbreaks of gastroenteritis caused by enteropathic E. coli

Topics: Articles
OAI identifier: oai:pubmedcentral.nih.gov:2496037
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.